...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology
【24h】

Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology

机译:基于肝病病因的同时肝肾移植的发生频率和预后

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The frequency of simultaneous liver kidney (SLK) transplantation is increasing. Data are scanty on outcomes of SLK transplants for liver disease etiology. METHODS: Outcomes for liver and kidney grafts and patients survival at 5 years were compared for liver disease etiology among adults receiving SLK during 2002 and 2011 in the United States. Cox regression analysis models were built to determine the independent impact of liver disease etiology on outcomes. RESULTS: A total of 2,606 patients (mean age 53 years, 69% males, 55% Caucasians) received SLK for primary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (n=945), alcoholic liver disease (n=495), alcohol and HCV (n=152), cryptogenic cirrhosis (CC, n=289), nonalcoholic steatohepatitis (NASH) (n=221), hepatitis B virus (HBV) (n=98), and hepatocellular carcinoma (HCC) (n=249). HCV and NASH+CC contributed to about 44% and 9%, respectively, of all SLK transplants in 2002. Corresponding figures in 2011 were 34% and 22%, respectively. Compared to PBC, 5-year outcomes were worse for NASH, HCV, and HCC for liver graft (72%, 66%, and 72% vs. 82%; hazard ratio, HR: 2.5-3.1), kidney graft (71%, 65%, and 71% vs. 80%; HR: 2.3-2.8), and patient survival (74%, 69%, and 69% vs. 82%; HR: 2.4-2.7). Follow-up renal function assessed at 1, 3, and 5 years showed poor renal function among patients receiving SLK for HCV, NASH, CC, and HBV. CONCLUSIONS: Frequency of SLK transplants is increasing among NASH patients. Overall graft and patient outcomes are good. However, SLK for NASH, HCV, and HCC do worse. Strategies are needed to improve outcomes for SLK in HCV and NASH patients.
机译:背景:同时肝肾(SLK)移植的频率正在增加。对于肝病病因,SLK移植的结果还很少。方法:比较了2002年至2011年在美国接受SLK的成年人的肝脏和肾脏移植物的结局以及患者5年生存率的肝脏疾病病因。建立Cox回归分析模型来确定肝病病因对结果的独立影响。结果:共有2606名患者(平均年龄53岁,男性占69%,白种人55%)因原发性胆汁性肝硬化(PBC,n = 76),原发性硬化性胆管炎(n = 81),丙型肝炎病毒(HCV)接受了SLK (n = 945),酒精性肝病(n = 495),酒精和HCV(n = 152),隐源性肝硬化(CC,n = 289),非酒精性脂肪性肝炎(NASH)(n = 221),乙型肝炎病毒(HBV) )(n = 98)和肝细胞癌(HCC)(n = 249)。 HCV和NASH + CC分别占2002年所有SLK移植的约44%和9%。2011年的相应数字分别为34%和22%。与PBC相比,NASH,HCV和HCC肝移植的5年结局更差(分别为72%,66%和72%和82%;危险比,HR:2.5-3.1),肾移植(71%) ,65%和71%与80%; HR:2.3-2.8)和患者生存率(74%,69%和69%与82%; HR:2.4-2.7)。在1、3和5年评估的随访肾功能显示,接受SLK治疗的HCV,NASH,CC和HBV患者的肾功能不佳。结论:NASH患者中SLK移植的频率正在增加。总体移植物和患者预后良好。但是,用于NASH,HCV和HCC的SLK表现更差。需要采取策略来改善HCV和NASH患者的SLK结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号